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IMPORTANCE In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist
in the clinical assessment of suspected Alzheimer disease.
OBJECTIVE To determine the sensitivity and specificity of positron emission tomography
imaging with flutemetamol injection labeled with radioactive fluorine 18 to detect β-amyloid
in the brain using neuropathologically determined neuritic plaque levels as the standard of
truth.
DESIGN, SETTING, AND PARTICIPANTS Open-label multicenter imaging study that took place at
dementia clinics, memory centers, and hospice centers in the United States and England from
June 22, 2010, to November 23, 2011. Participants included terminally ill patients who were
55 years or older with a life expectancy of less than 1 year.
INTERVENTIONS Flutemetamol injection labeled with radioactive fluorine 18 (Vizamyl; GE
Healthcare) administration followed by positron emission tomography imaging and
subsequent brain donation.
MAIN OUTCOMES ANDMEASURES Sensitivity and specificity of flutemetamol injection labeled
with radioactive fluorine 18 positron emission tomography imaging for brain β-amyloid.
Images were reviewed without and with computed tomography scans and classified as
positive or negative for β-amyloid by 5 readers who were blind to patient information. In
patients who died, neuropathologically determined neuritic plaque levels were used to
confirm scan interpretations and determine sensitivity and specificity.
RESULTS Of 176 patients with evaluable images, 68 patients (38%) died during the study,
were autopsied, and had neuritic plaque levels determined; 25 brains (37%) were β-amyloid
negative; and 43 brains (63%) were β-amyloid positive. Imaging was performed amean of 3.5
months (range, 0 to 13 months) before death. Sensitivity without computed tomography was
81% to 93% (median, 88%). Median specificity was 88%, with 4 of 5 of the readers having
specificity greater than 80%.When scans were interpreted with computed tomography
images, sensitivity and specificity improved for most readers but the differences were not
significant. The area under the receiver operating curve was 0.90. There were no clinically
meaningful findings in safety parameters.
CONCLUSIONS AND RELEVANCE This study showed that flutemetamol injection labeled with
radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life
population. In vivo detection of brain β-amyloid plaque density may increase diagnostic
accuracy in cognitively impaired patients.
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T he neuropathological hallmarks of Alzheimer disease(AD),β-amyloid (Aβ)plaquesandneurofibrillary tangleshave long been used to definitively diagnose the dis-
ease post mortem1 but the inability to detect these hallmarks
in life renders clinical diagnosis of AD imperfect. For ex-
ample, Beach et al2 reported 71% to 87% sensitivity and 44%
to71%specificity for clinicaldiagnosisofADbasedon919cases
in the National Alzheimer Coordinating Center database and
Salloway et al3 found that among patients diagnosed as hav-
ingprobableAD,6.5%ofapolipoproteinEε4carriers and36.1%
of ε4 noncarriers were amyloid negative by positron emis-
sion tomography (PET) amyloid imaging. Because Aβ is char-
acteristic of ADpathology, its detection in vivomay support a
clinical diagnosis of AD while its absence would make AD
unlikely.4-7 Historically, Aβ plaques have been detected post
mortem using stains with high affinity for amyloid aggre-
gates (eg, thioflavin S/T, Congo red) or dystrophic neurites in
neuritic plaques (Bielschowsky silver stain). Recently, PET
imaging agents (eg, Pittsburgh compound B [PiB],
flutemetamol, florbetapir, florbetaben,andAZD4694)werede-
veloped to detect cerebral Aβ in vivo8-13 and 3 drugs
(florbetapir14 [amyvid; Eli Lilly], flutemetamol [vizamyl; GE
Healthcare], and florbetaben [neuraceq; Piramal]) arenowap-
proved in the United States and Europe.
PittsburghcompoundBandflutemetamol,whicharestruc-
turally similar to thioflavin T and to one another, bind to Aβ
with high affinity15,16 and clear rapidly from normal brain
tissue.17 Prior flutemetamol studies showed good brain up-
take and radiation dosimetry similar to other radiopharma-
ceuticals inclinicaluse,17 test-retestvariability for imagequan-
titation (standarduptakevalue ratio, 1%-4%),11 differentiation
betweenhealthyparticipants andpatientswithAD,11,17 and the
ability to detect brain Aβ.18-20
In this study, we compared interpretations of
[18F]flutemetamol PET images with brain Aβ levels (deter-
minedpostmortemas the standardof truth) todeterminePET
sensitivity and specificity.
Methods
Participants and Study Design
This was a phase 3 multicenter PET study of flutemetamol in-
jection labeledwith radioactive fluorine 18 ([18F]flutemetamol)
fordetectingbrainAβ. Institutional reviewboardsorethicscom-
mittees at the following institutions approved the studyproto-
colbefore initiation:CompassResearch,GalizResearch,LasVe-
gas Radiology, Premier Research Institute, Banner Sun Health
ResearchInstitute,MtSinaiMedicalCenter,WienCenter forAlz-
heimer’s Disease,WarrenAlpertMedical School of BrownUni-
versity, Banner Alzheimer’s Institute, University of Michigan,
Moorgreen Hospital, VERITAS Research, St Margaret’s Hospi-
tal,Miami JewishHealthSystems,MemoryEnhancementCen-
ter, Oxford Radcliffe Hospitals, Michigan State University, Ex-
odonLLC, andBarrowsNeurological Institute.All participants
or their legal representatives provided prior written informed
consent.Consecutiveeligibleparticipantswere55yearsorolder,
terminally illwitha lifeexpectancyof1yearor less,andhadgen-
eral health adequate to undergo study procedures. Partici-
pants were ineligible if they were pregnant/lactating, had
known/suspected structural brain abnormalities, contraindi-
cation(s) for PET, known/suspectedhypersensitivity/allergy to
[18F]flutemetamol injection (or any component), or had par-
ticipated in any clinical studyusing an investigational product
within 30 days of signing consent.
The primary study objective was to determine the sensi-
tivityofblindedvisual interpretationsof [18F]flutemetamolPET
images alone for detecting brain Aβ. Secondary objectives in-
cluded specificity, and sensitivity and specificity when com-
puted tomography (CT) imageswere available duringPET im-
age review.
Procedures
Consenting patients were enrolled at centers in the United
States andEngland.For statistical analyses, patientswere clas-
sified as having an entry diagnosis of AD, another dementing
disorder,mild cognitive impairment,memory loss, or no cog-
nitive impairment at screening based on a review of reported
medical historydata. TheMini-Mental StateExaminationwas
performedat screening.21BeforePET imaging,participantsun-
derwent headCTormagnetic resonance imaging unless prior
images (obtained within 12 months) were available.
Flutemetamol injection labeled with fluorine 18 was admin-
istered intravenously at a dose of 185 to 370 MBq of radioac-
tivity at physician discretion based on how long the patient
could lie in the scanner. Positron emission tomography im-
ageswereacquired in2-minute framesonPET/CTcameras, be-
ginning approximately 90minutes postinjection. Five frames
weresummedtogivea10-minutescan,whichwasattenuation-
corrected using CT data. Most images were reconstructed it-
eratively to form 128 × 128 axial slices and a gaussian postre-
construction smoothing filter was applied to some. Imaging
parameters had been developed in a prior phase 2 study.11
Safety was monitored from injection to 4 hours after scan-
ning and 24 hours after injection (by telephone).
For theblindedread,PET imageswere randomizedandap-
proximately 10% of these images were duplicated and ran-
domly combined with the other images to measure within-
reader reproducibility. Five readers (4 nuclear medicine
physicians and 1 radiologist) independently interpreted PET
scansatacentral reviewcenter.Eachreaderhadat least3years’
neuroimaging experience,was trained in person by an expert
nuclear medicine physician in evaluating [18F]flutemetamol
PET images, and was blinded to patient information. The 5
brain regions assessed were the combined lateral frontal cor-
tex and anterior cingulate, combined posterior cingulate and
precuneus, insula, lateral temporal lobes, and striatal re-
gions. Images were displayed in color (Sokoloff color scale)22
scaled from0 tomaximum intensity. All images showednon-
specific flutemetamol uptake bywhitematter; the absence of
a similar level of uptake in any gray matter area indicated a
negative image. Positive images showed at least 1 graymatter
areawithuptakesimilar toorgreater thanthat seen in thewhite
matter and cerebellar cortex.
After readers interpreted the PET images and locked their
decisions, imageswere rerandomized and rereadwith CT im-
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ages for anatomic guidance. Between-reader agreement and
within-reader reproducibilityweredetermined for thePET in-
terpretations. The interpretation of each PET imagemade in-
dependently by at least 3 of 5 readerswas considered thema-
jority image interpretation.
Standard of truth results were obtained from partici-
pants who died during the study and underwent brain au-
topsy. Postmortem histopathology was performed at a cen-
tral pathology laboratory. Brain regions assessed were the
precuneus, midfrontal lobe, superior temporal, middle tem-
poral, anterior cingulate, posterior cingulate, primary visual
cortex, and inferiorparietal. Twoblocksper regionand3 slides
per block were prepared. Sections were stained with Biel-
schowsky silver stain.23 Twoneuropathologists (blinded to all
PET data and participant clinical information) assessed 5 ran-
domly chosen fieldsof view (approximately 2.5mm2)per slide
simultaneously, using a 2-headed microscope, and reached
consensus on neuritic plaque counts following Vemurimodi-
fication of the Consortium to Establish a Registry for Alzhei-
mer Disease criteria: 0 (none), 1 (sparse, 1-5 plaques), 2 (mod-
erate, 6-19 plaques), or 3 (frequent, >20 plaques).1,24 Field of
viewscoreswere averaged to give slide scores,whichwere av-
eraged to give regional scores. Each brain was classified as
either negative (all regional scores ≤1.5 [the midpoint of the
ConsortiumtoEstablishaRegistry forAlzheimerDiseasescale])
or positive (any regional score >1.5).
Theblindedvisual interpretationsofPETimageswerecom-
paredwith thepostmortembrainAβresultsandsensitivityand
specificity were determined for each reader. To obtain a neu-
ropathological diagnosis including cerebral amyloid angiopa-
thy, tissuewas also stainedby immunohistochemistry forAβ,
tau, α-synuclein, and ubiquitin. Quantitative analysis of im-
ages (standard uptake value ratio) was performed andwill be
reported separately.
Statistical Analysis
Populations analyzed included the safety cohort (partici-
pants receiving any flutemetamol dose), full cohort (partici-
pants with usable PET results), and postmortem cohort (par-
ticipants with postmortem Aβ results). Sensitivity and
specificity were determined as point estimates with exact
2-sided 95% CIs. Between-reader agreement and within-
reader reproducibility were determined as percentage agree-
ment and κ coefficient. All data were reported and no impu-
tation for missing data was done. Areas under receiver
operating characteristic (ROC) curvesweredeterminedbycal-
culating the area of trapezoids defined by the curves.
The null hypothesis related to the precision of sensitivity
estimation, as indicated by the width of the 95% CI; the null
hypothesis was that the lower bound of the 95% CI for sensi-
tivitydetermined for a blinded readerwas 70%or less, assum-
ing a true sensitivity of 92%. Sample size calculations showed
that 31 brains that were Aβ positive post mortem would pro-
vide approximately 90% power to reject the null hypothesis.
The study would be considered a success if the null hypoth-
esis was rejected for at least 3 of the 5 readers. Based on simi-
lar calculations for specificity (assuming a true specificity of
95%), itwas also planned to accrue at least 22 brains thatwere
Aβ negative post mortem. An independent data monitoring
committee reviewed the pathology data on an ongoing basis
and reported the numbers of Aβ-positive and Aβ-negative
brains at regular intervals.
Results
Between June 22, 2010, and November 23, 2011, 203 partici-
pants consented and enrolled at 19 centers (dementia clinics,
memory centers, and hospice centers; 15 in theUnited States,
4 in England); eFigure 1 in the Supplement shows participant
dispositionandTable 1 showsbaselinedemographicsandchar-
acteristics. Most participants had existing neurologic (83%),
cardiovascular (73%), digestive (64%), psychiatric (57%), and
musculoskeletal (52%) conditions at baseline. For the 180par-
ticipants who were dosed and imaged, the mean (SD) dose
(megabecquerel radioactivity)was 349.2 (38.358); 86%ofpar-
ticipants received370 ± 10%MBq,2%received185 ± 10%MBq,
and 12% received between 185 and 370MBq. All images were
of good technical quality; none were considered unevalu-
able. Images from 4 participants (2.2%) were excluded from
analysis because the participants did not complete the study.
For these end-of-life patients, the time to remain motionless
ina loudmagnetic resonance imaging scannerwasdeemedex-
cessive for practical and ethical reasons; hence, few mag-
netic resonance imageswereobtainedandnonewereusedbe-
cause all patients had received a CT scan within 12 months.
Amongparticipantswhodied, [18F]flutemetamolPETwas
performed amean of 3.5 months (range, 0-13 months) before
death.Of the68evaluablebrains, 25brains (37%)wereAβnega-
tive and 43 (63%) were Aβ positive. Histopathology showed
varying levels of neuritic plaque density from none to fre-
quent, with asmany as 60% of samples consideredmoderate
or frequent (Figure).
Table 2 shows by-reader results of the primary end point,
which was sensitivity. Sensitivity was 81% to 93% (median,
88%; majority, 86%). The lower bound of the 2-sided 95% CI
wasmore than 70% for at least 3 of the 5 readers,meeting the
primaryobjectiveof thestudy.Specificitywas44%to92%(me-
dian,88%;majority,92%).Whenreaders interpretedPETscans
withCT images, sensitivity and specificity improved formost
readers but the differences were not significant (data not
shown). Possible reasons for the outlying specificity value
(reader 3) are discussed below. The area under the ROC curve
for flutemetamolwithoutCT(eFigure2 in theSupplement)was
0.90 (95%CI, 0.82-0.97), comparing favorablywith a theoreti-
cal value of 1.0 for a perfect test.
Pairwise between-reader agreement (Table 3)was 90%or
higher without or with CT except for comparisons involving
reader 3 (80%-88%); κ scores were also lower for reader 3. κ
scoreswerehigherwithCT.Within-reader reproducibilitywith-
out and with CT images was 88% to 100% and 82% to 100%,
respectively, and κ ranges were 0.60 to 1.00 and 0.30 to 1.00,
respectively (Table 4).
Based on the majority interpretations of PET, 6 of the 43
participantswhowereAβpositive (14%)hadfalse-negative (FN)
interpretations and2of the 25participantswhowereAβnega-
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tive (8%)had false-positive (FP) interpretations. eTable 1 in the
Supplement showscharacteristics forparticipantswithFN,FP,
andcorrect image interpretations. eFigure3 in theSupplement
shows thePETandPET/CT images for theFPandFNcases that
were not borderline in pathology (Figure), as well as ex-
amples of unequivocal negative and positive cases. Summa-
ries of the pathology of these nonborderline cases are in-
cluded. Although caution should be exercised in interpreting
the data based on small sample sizes, the FN casesweremore
likely to have no history of cognitive impairment and the FP
cases were more likely to have a history of a non-Alzheimer
formofdementia.Allof theFNandFPcaseshadsparseormod-
erate neuritic plaque densities andweremore likely to have a
low likelihoodofADaccording to theNational Institute ofAg-
ing–Reagan Institute criteria.25
eTable 2 in the Supplement lists reported adverse events.
Flushing (n = 2), consideredpossibly related to flutemetamol,
was mild and did not require treatment. Deaths were
expected based on the main inclusion criterion (life expec-
tancy, ≤1 year). Of the 180 dosed participants, 69 (38%) died
during the study; 2 deaths occurred within the 24-hour
follow-up period and were reported as the outcome of seri-
ous adverse events (prostate cancer and senile dementia).
No death was considered related to flutemetamol. Nonfatal
serious adverse events (considered unrelated to study drug)
were reported for 2 participants, a case of severe anemia
and a case of change in mental status caused by a combina-
tion of AD progression and Clostridium difficile infection. All
other adverse events were mild or moderate. No clinically
important trends or issues were noted in any safety param-
eter, including clinical laboratory values, vital signs, and
electrocardiograms.
Discussion
In this study, blinded interpretationof [18F]flutemetamol PET
images allowed in vivo detection of Aβ in the brain with high
sensitivity, specificity,between-readeragreement, andwithin-
reader reproducibility.Flutemetamol injection labeledwith ra-
Table 1. Patient Demographics and Characteristics
Statistic
Analysis Set
Safety
(n = 180)
Full
(n = 176)
Postmortem
(n = 68)
Characteristic
Age, ya
Sample size 180 176 68
Mean (SD) [range] 79.9 (9.61) [47-98]b 80.0 (9.59) [47-98]b 80.8 (8.19) [60-95]
Sex, No. (%)
Male 77 (43) 75 (43) 33 (49)
Female 103 (57) 101 (57) 35 (51)
Race/ethnicity, No. (%)
Asian 1 (1) 1 (1) 0
Black 7 (4) 6 (3) 2 (3)
White 168 (93) 165 (94) 64 (94)
Other 4 (2) 4 (2) 2 (3)
Race/ethnicity, No. (%)
Non-Hispanic or Latino 139 (77) 135 (77) 46 (68)
Hispanic or Latino 41 (23) 41 (23) 22 (32)
MMSE
Sample sizec 123 119 42
Mean (SD) [range] 8.5 (10.39) [0-30] 8.5 (10.50) [0-30] 9.8 (10.47) [0-30]
Clinical diagnosis, No. (%)d
Alzheimer disease 87 (48) 84 (48) 30 (44)
Other dementing disorder 48 (27) 47 (25) 17 (25)
Parkinson disease with dementia 1 1 1
Frontotemporal dementia 2 2 1
Dementia with Lewy bodies 4 4 1
Vascular dementia 1 1 1
Normal pressure hydrocephalus 2 2 2
Unspecified 38 37 11
Mild cognitive impairment 0 0 0
No history of cognitive impairment 44 (24) 44 (25) 21 (31)
Memory loss (unspecified) 1 (1) 1 (1) 0
Abbreviation: MMSE, Mini-Mental
State Examination.
a Age was calculated as (date of
informed consent minus date of
birth)/365.25 rounded down to the
nearest integer.
bOne patient with end-stage renal
disease and a life expectancy of less
than 6months was given a waiver
to enroll in the study because the
age difference was not expected to
affect subject safety or efficacy
evaluation.
c Number of patients with
nonmissing data for MMSE.
dClinical diagnosis was determined
based on reportedmedical history.
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dioactive fluorine 18 was well tolerated in this population of
terminally ill patients.
Despitea trainingprogramconducted inpersonbyanexpe-
riencednuclearmedicinephysician, thespecificityofoneof the
readers (reader3)was lowercomparedwith theother4readers.
ThelowerspecificitywasowingtoahighFPrate, indicatingover-
callingforamyloid.Subsequenttothisstudy,anelectronicreader
trainingprogramwasdesignedusingmoreequivocal casesand
wasmade available to image readers.26 This program requires
trainees to correctly interpret 14 of 15 cases to pass the training
andwe believe it will result in greater reader accuracy.
By themajority image interpretation, 8 incorrect results (6
FNcases and2FPcases) occurred.NoFNorFPcasewasattrib-
utable topoor imagequality.Detailedassessmentof thesecases
(eTable 1 in theSupplement) showedthemoststrikingcommon
denominator tobeaConsortiumtoEstablishaRegistry forAlz-
heimerDiseaseneuriticplaquedensity ratingof sparseormod-
erate. In 4 FN cases, the neuritic plaque scorewas close to the
threshold,suggestingthesewereborderlinecases.TwoFNcases
hadneuropathologicalevidenceconsistentwithdementiawith
Lewy bodies. Two FPs occurred in patients who had a neuro-
pathological diagnosis of dementiawith Lewybodies andhad
diffuse plaques aswell as sparse ormoderate neuritic plaques
thatwerebelowthethresholdforstandardoftruth.Patientswith
thispresentationwouldhaveintermediatelikelihoodofADusing
themorerecentcriteria.27These findingsareconsistentwithre-
sults obtained with PiB in patients with dementia with Lewy
bodies.28EachFNcasealsohadsomedegreeofcortical atrophy
and2FNcases became true-positive caseswhenanatomic im-
ageswereused,possibly throughbetterdelineationof thegray
andwhitematter. eFigure4 in theSupplement shows thePET/
CT images of the FN andFP cases that did not have borderline
pathology; patient summaries are included.
TwootheramyloidPET imagingagents (florbetapirandflo-
rbetaben) are approved in theUnitedStates andEurope.None
of the3PETagentshavebeencomparedhead tohead inaclini-
cal trial and the results from independent studies should be
compared cautiouslyowing todifferences in studydesignand
population. For example, the distribution of neuritic plaque
densities for the florbetapir participantswasmarkedly differ-
ent from the distributions for flutemetamol and florbetaben
(eTable 3 in the Supplement).With these caveats inmind, by-
reader sensitivity and specificity were determined from data
reported in the US package inserts for florbetapir9,29 and
florbetaben30 (eTable 4 in the Supplement). Direct compari-
son of these data is difficult because florbetaben and
flutemetamol readers tended to have higher sensitivity than
florbetapir readers, who tended to have higher specificity. To
facilitate comparison,weconstructedROCcurves for the read-
ers (data not shown). The area under the ROC curve provides
a single measure of diagnostic test performance; the area for
a perfect test is 1 and the area for a useful test is greater than
0.5.31 Theareasunder theROCcurves for flutemetamol (0.90),
florbetaben (0.90), and florbetapir (0.85) were not signifi-
cantly different (2-tailed, P = .34-.92).
Our study had some limitations. The number of readers
(5), although typical for a clinical trial, may not represent the
population of nuclearmedicine physicianswhowill read PET
amyloidscans.Majority interpretationsprovidedasinglenum-
berbutdidnot simulate clinicalpracticewhere imagesare read
bya single reader.Quantitativemeasurementof flutemetamol
uptake, althoughnot included in theprimaryoutcome for this
trial, may add important information to the interpretation of
amyloid PET scans. Patients’ cognitive capacitywas recorded
based on medical history and Mini-Mental State Examina-
tion;no furtherneurobehavioral testingwasperformed.How-
ever, it is unlikely that the resultswouldhave affected the cor-
relationbetween imaging andpathology,whichwas the focus
of the article. The variable, sometimes long, time between
imaging and autopsy may have contributed to lack of agree-
Figure. Standard of Truth (SoT) Results for Each Participant Sorted byMean Bielschowsky Score
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ment betweenPET imaging andhistopathology results in cer-
tain cases. The study’s end-of-life population (required to al-
lowautopsy)maynotcompletely reflect thepatientpopulation
expected to undergo amyloid PET imaging in clinical prac-
tice. For example, noparticipantswithmild cognitive impair-
ment, a populationwhomay benefit from amyloid PET, were
included in this sample. Results of a recent study showed that
patients with amnestic mild cognitive impairment who had
positive [18F]flutemetamol scanswere 2.6 timesmore likely to
progress toprobableAD than thosewithnegative scans.32 Fur-
ther research is needed to elucidate theutility of amyloid PET
in mild cognitive impairment. Finally, reader training in this
studywasconducted inperson,whereas refinedelectronicver-
sions have been developed.
Detectingamyloid isnot synonymouswithdiagnosingAD.
Amyloid PET should only be ordered in the appropriate clini-
cal context, eg, after completion of a detailed evaluation by a
dementia expert results in diagnostic uncertainty, AD is a se-
rious consideration, and the result of the amyloid PET scan is
likely to alter patient management.6,7
Conclusions
In vivo detection of brainAβmayhelp increase diagnostic ac-
curacy in cognitively impaired patients compared with clini-
cal diagnosis alone.This study showed that [18F]flutemetamol
injection was safe and had high sensitivity and specificity in
an end-of-life population with a broad and continuous range
of Aβ levels in the brain.
Table 2. Sensitivity and Specificity of Blinded Visual Interpretation of
Flutemetamol Imagesa
Reader
% (95% CI)
Sensitivityb Specificityc
1 81 (67-92) 88 (69-98)
2 88 (74-96)d 92 (74-99)
3 93 (81-99)d 44 (24-65)
4 93 (81-99)d 80 (59-93)
5 88 (75-96)d 92 (74-99)
Median 88 (74-96) 88 (69-98)
Majority 86 (72-95) 92 (74-99)
a Data are rounded to the nearest integer.
b Sensitivity = true positives/(true positives + false negatives).
c Specificity = true negatives/(true negatives + false positives).
d Two-sided 95% CI with a lower bound greater than 70%.
Table 3. Summary of Between-Reader Agreement for Blinded Visual InterpretationsWithout andWith Anatomic Images
Reader Pair
Anatomic Images
Without With
Sample Sizea Agreement, No. (%) κb 95% CI Sample Sizea Agreement, No. (%) κb 95% CI
1 vs 2 175 159 (91) 0.79 0.69-0.89 175 166 (95) 0.87 0.79-0.95
1 vs 3 176 140 (80) 0.47 0.34-0.61 176 148 (84) 0.56 0.43-0.70
1 vs 4 175 164 (94) 0.85 0.77-0.94 176 171 (97) 0.93 0.87-0.99
1 vs 5 176 169 (96) 0.91 0.84-0.98 175 173 (99) 0.97 0.94-1.00
2 vs 3 175 148 (85) 0.55 0.41-0.69 175 154 (88) 0.64 0.50-0.77
2 vs 4 175 158 (90) 0.76 0.65-0.87 175 165 (94) 0.86 0.77-0.94
2 vs 5 175 163 (93) 0.84 0.75-0.93 174 167 (96) 0.90 0.83-0.97
3 vs 4 175 141 (81) 0.44 0.29-0.59 176 149 (85) 0.56 0.43-0.70
3 vs 5 176 145 (82) 0.52 0.39-0.66 175 149 (85) 0.58 0.45-0.72
4 vs 5 175 168 (96) 0.90 0.84-0.97 175 172 (98) 0.96 0.91-1.00
Readers 1-5 175 131 (75) 0.72 0.67-0.76 174 143 (82) 0.79 0.75-0.84
a Number of images with nonmissing values for the respective reader pair.
b Cohen κ coefficient reported for between-reader agreement. Fleiss κ coefficient reported for multiple reader agreement.
Table 4. Summary ofWithin-Reader Reproducibility for Blinded Visual InterpretationsWithout andWith Anatomic Images
Reader
Anatomic Images
Without With
Sample Sizea Agreement, No. (%) κb 95% CI Sample Sizea
Agreement to
No. (%) κb 95% CI
1 17 16 (94) 0.85 (0.57 to 1.00) 17 16 (94) 0.85 (0.57 to 1.00)
2 17 17 (100) 1.00 NE 17 17 (100) 1.00 NE
3 17 15 (88) 0.60 (0.09 to 1.00) 17 14 (82) 0.30 (−0.29 to 0.90)
4 17 17 (100) 1.00 NE 17 16 (94) 0.85 (0.57 to 1.00)
5 17 17 (100) 1.00 NE 17 17 (100) 1.00 NE
Abbreviation: NE, not estimable.
a Number of images selected for reread.
bCohen κ coefficient reported for within-reader agreement.
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